GO:0038132 neuregulin binding: Mechanism, Genes and Research

Neuregulin binding (GO:0038132) is a molecular function that describes the selective interaction of a protein with a neuregulin, a member of the epidermal growth factor (EGF) family of growth factors. Neuregulins are encoded by four genes (NRG1–NRG4) and act as paracrine or juxtacrine signals that regulate cell proliferation, differentiation, survival, and migration in multiple tissues. The binding event is the first step in a signaling cascade that typically involves ErbB/HER receptor tyrosine kinases, most notably HER3 (ERBB3) and HER4 (ERBB4), and their heterodimeric partners such as HER2 (ERBB2). Because neuregulin binding is a point of control for these pathways, it is a central node in cancer biology, cardiovascular development, and metabolic regulation. Researchers study neuregulin binding to understand how extracellular cues are translated into intracellular signals. The interaction between NRG1β and the HER2–HER3 complex has been resolved structurally, revealing a dynamic dimer interface that explains how ligand binding triggers receptor activation. Beyond canonical ErbB signaling, neuregulin-1 (NRG1) can bind to allosteric sites on integrins and suppress inflammatory cytokine-mediated integrin activation, suggesting a broader role in cell adhesion and inflammation. In adipose tissue, neuregulin 4 (NRG4) downregulation alters mitochondrial morphology and induces oxidative stress, linking neuregulin binding to metabolic homeostasis. These findings underscore the importance of neuregulin binding as a molecular function that bridges extracellular signals to diverse cellular outcomes. The clinical relevance of neuregulin binding is underscored by its involvement in cancer. Neuregulin-ErbB signaling is pro-oncogenic in several tumor types, and its dysregulation can promote tumor growth and resistance to therapy. In the tumor microenvironment, neuregulin signaling mediates crosstalk between cancer cells and stromal cells, influencing angiogenesis and immune evasion. Additionally, adipocyte-derived exosomes can transfer neuregulins to breast cancer cells, driving primary mammary cancer progression. These observations position neuregulin binding as a promising target for therapeutic intervention and a subject of intense research.

Neuregulin binding (GO:0038132) is the molecular function of selectively interacting with a neuregulin, a member of the EGF family of growth factors. This binding event is typically mediated by extracellular domains of receptor tyrosine kinases (e.g., ERBB3, ERBB4) or other cell-surface or secreted proteins, and it initiates or modulates downstream signaling.

Neuregulin binding is a critical molecular function because it initiates signaling cascades that control fundamental cellular processes such as proliferation, survival, differentiation, and migration. Dysregulation of neuregulin binding is implicated in cancer progression, where it can drive tumor growth and therapeutic resistance. In the tumor microenvironment, neuregulin signaling mediates communication between cancer cells and stromal components, influencing angiogenesis and immune responses. Beyond cancer, neuregulin binding plays roles in adipose tissue biology and metabolic regulation, as shown by NRG4 downregulation leading to mitochondrial dysfunction and oxidative stress in adipocytes. NRG1 binding to integrins also suggests a role in inflammation and fibrosis. Thus, understanding neuregulin binding is essential for both basic biology and translational medicine.

The following genes encode proteins that bind neuregulins or are directly involved in neuregulin-binding complexes and downstream signaling.

Neuregulin binding and its downstream signaling are regulated at multiple levels. Ligand availability is controlled by expression, alternative splicing, and proteolytic cleavage of neuregulin precursors. Receptor levels and dimerization partners influence signal strength; for example, ERBB3 requires heterodimerization with ERBB2 for efficient signaling. Intracellular negative regulators such as PDCD4 can limit neuregulin-ErbB signaling by inhibiting ERK and AKT activation. Additionally, inflammatory cytokines can modulate integrin activation, which may compete with or be suppressed by NRG1 binding to integrins. Metabolic states also affect neuregulin signaling; NRG4 downregulation in adipocytes alters mitochondrial dynamics and induces oxidative stress, suggesting feedback regulation by cellular stress.

Dysregulated neuregulin binding is a hallmark of several cancers. Overexpression of NRG1 or its receptors ERBB2 and ERBB3 leads to constitutive activation of PI3K/AKT and MAPK pathways, promoting tumor cell proliferation, survival, and metastasis. In breast cancer, adipocyte-derived exosomes can transfer neuregulins to cancer cells, enhancing primary mammary cancer progression. PDCD4 loss further amplifies neuregulin-ErbB signaling, contributing to oncogenesis. Targeting neuregulin binding with monoclonal antibodies or small molecules is an active therapeutic strategy.

NRG4 is highly expressed in adipose tissue and plays a role in metabolic homeostasis. Downregulation of NRG4 in 3T3-L1 adipocytes alters mitochondrial morphology and induces oxidative stress, linking neuregulin binding to mitochondrial function and metabolic disease. This suggests that neuregulin binding to ERBB4 in adipocytes may regulate energy balance and insulin sensitivity. Further research is needed to fully elucidate these mechanisms.

NRG1 binds to the allosteric site of integrins and suppresses inflammatory cytokine-mediated integrin activation, indicating an anti-inflammatory mechanism. This binding may also contribute to anti-fibrotic effects, as integrin activation is involved in fibrotic remodeling. These findings suggest that neuregulin binding could be harnessed for therapeutic benefit in inflammatory and fibrotic diseases.

Browning and mobilization of subcutaneous white adipose tissue supports efficient skin repair, and neuregulin signaling may be involved in this process. Although direct evidence for neuregulin binding in skin repair is limited, the interplay between adipose tissue and skin regeneration highlights potential roles for neuregulin-ErbB signaling in wound healing.

Structural studies such as cryo-EM have resolved the NRG1β–HER2–HER3 complex, revealing the dynamic dimer interface and ligand-binding pocket. These methods provide atomic-level details of neuregulin binding and guide the design of inhibitors.

Surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC) measure binding affinity and kinetics between neuregulins and their receptors or integrins. Co-immunoprecipitation can confirm interactions in cell lysates.

Western blotting for phosphorylated ERK and AKT assesses downstream signaling activation upon neuregulin stimulation. Phospho-array kits can profile multiple pathways simultaneously.

Genome-wide CRISPR knockout screens can identify genes that regulate neuregulin binding and signaling. For example, screens in cancer cells treated with neuregulin can reveal synthetic lethal interactions.

Researchers studying neuregulin binding-related genes often need to determine whether a candidate gene is causally involved in a specific signaling pathway or disease phenotype. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this discovery process, from gene knockout to precise point mutations and knock-in models.

Neuregulin binding (GO:0038132) is a fundamental molecular function that initiates critical signaling cascades through ErbB receptors and other targets such as integrins. Its dysregulation is linked to cancer, metabolic disorders, and inflammation, making it a focal point for both basic and translational research. Understanding the structural and functional details of neuregulin binding provides opportunities for therapeutic intervention. EDITGENE's CRISPR services, including knockout, point mutation, knock-in, overexpression, and library screening, empower researchers to dissect the causal roles of neuregulin-binding proteins in health and disease. By leveraging these tools, the scientific community can accelerate discoveries that may lead to novel treatments targeting neuregulin signaling.